{"prompt": "['Novartis', 'Confidential', 'Page 13', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'these doses as well as other statins will be permitted during the study.', 'Patients on rifampin, probenecid, ritonavir and valproic acid (i.e.,', 'medications blocking several pathways important for the elimination of', 'QAW039 (broad range uridinediphosphate glucuronosyltransferase', '(UGT) inhibition and/or inhibition of organic anion transporter 3 (OAT3),', 'organic anion transporter P1B3 (OATP1B3), multi-xenobiotic resistance', 'protein (MXR) and p-glycoprotein (P-gp)).', 'Patients on any statin therapy with a creatine kinase (CK) level >2 X', 'ULN (upper limit of normal) at Visit 1.', 'Patients with a history of conditions other than asthma or allergic rhinitis', 'that could result in elevated eosinophils (e.g., hypereosinophilic', 'syndromes, Churg-Strauss Syndrome, eosinophilic esophagitis).', 'Patients with known parasitic infestation within 6 months prior to Visit 1', 'are also excluded.', 'Study treatment', 'QAW039 150 mg once daily', 'Placebo once daily', 'Key efficacy', 'Lung function (FEV1)', 'assessments', 'Asthma symptoms', 'Short-acting \u00df-agonist (SABA) use', 'AQLQ+12', 'Key safety assessments', 'Adverse event monitoring', 'Physical examinations', 'Vital signs', 'Laboratory examinations of blood and urine', 'ECG', 'Data analysis', 'The primary variable for this study is the change from baseline in pre-dose', 'FEV1 at the end of 12 weeks of treatment. Pre-dose FEV1 is the average', 'of the 2 FEV1 assessments taken at 45 minutes and 15 minutes prior to the', 'dosing of study drug at the clinic visit. The baseline FEV1 is defined as', 'mean of the last two FEV1 assessments prior to the first dose of study', 'drug. If any one of these assessments is missing (or is not confirmed to be', 'pre-dose), then the remaining non-missing observation will be considered', 'as baseline. If both assessments are missing (or are not confirmed to be', 'pre-dose) then the last available FEV1 measurement prior to Day 1 on', 'study drug will be used for baseline. If the FEV1 measurements are', 'missing both on Day 1 and at the placebo run-in or screening visits, the', 'respective baseline values will be set to missing. Missing data after', 'discontinuation of double-blind study treatment will be imputed using the', 'jump-to-reference approach.', 'The secondary variables are daytime asthma symptoms, total daily SABA', 'use, and AQLQ+12.', 'Analysis of primary variable: The primary efficacy variable will be analyzed', 'on the full analysis set (FAS) using an analysis of covariance (ANCOVA)', 'model with factors for treatment group, age group (<18 VS. >18 years), use', 'or non-use of a second asthma controller medication, and region, as well', 'as the baseline daytime asthma symptom score, baseline total daily SABA', 'use and baseline pre-dose FEV1 as continuous linear covariates.']['Novartis', 'Confidential', 'Page 14', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'The least squares mean (\"adjusted mean\") change from baseline for each', 'treatment group, the difference in the least squares mean changes', 'between the two treatment groups (QAW039 150mg - placebo), and the', 'two-sided adjusted 95% confidence interval along with the p-value for the', 'difference will be obtained and combined from the primary analysis model', 'through the multiple imputation approach described in Section 9.4.3. The', 'superiority of QAW039 150 mg once daily to placebo as add on to existing', 'asthma therapy is established, if the two-sided p-value is less than 0.05', 'and the 95% confidence intervals lie entirely to the right of 0 L.', 'Analysis of secondary variables: The secondary variables of this study are', 'change from baseline in daytime asthma symptoms, change from baseline', 'in total daily SABA use, and change from baseline in AQLQ+12 over', 'the', '12-week active treatment period.', 'The mean of change from baseline in the daytime asthma symptom scores', 'over the 12 weeks of treatment will be analyzed using an analysis of', 'covariance (ANCOVA) model in a similar fashion as for the primary efficacy', 'variable.', 'The mean of change from baseline in the total daily use of SABA over the', '12 weeks of treatment will be analyzed using an ANCOVA model in a', 'similar fashion as for the primary efficacy variable.', 'The change from baseline in AQLQ+12 at week 12 will be analyzed using', 'an ANCOVA model in a similar fashion as for the primary efficacy variable.', 'Six hundred fifty (650) patients (325 per arm) are needed for 90% power to', 'observe a statistically significant difference between QAW039 and placebo', 'at the two-sided 5% significance level in the primary analysis, assuming a', 'treatment difference of 112 mL for the primary endpoint, a standard', 'deviation of 380 mL and a treatment discontinuation rate of 15% with half of', 'the patients discontinuing from study treatment having week 12', 'assessment of the primary variable.', 'Key words', 'QAW039, uncontrolled asthma']\n\n###\n\n", "completion": "END"}